List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Small Molecule CDMO Market, 2021-2031, $ mn 18
Figure 5. Impact of COVID-19 on Business 21
Figure 6. Primary Drivers and Impact Factors of North America Small Molecule CDMO Market 23
Figure 7. Primary Restraints and Impact Factors of North America Small Molecule CDMO Market 27
Figure 8. Investment Opportunity Analysis 31
Figure 9. Porter’s Fiver Forces Analysis of North America Small Molecule CDMO Market 34
Figure 10. Breakdown of North America Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 39
Figure 11. North America Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 39
Figure 12. North America Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 40
Figure 13. North America Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 41
Figure 14. North America Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 42
Figure 15. North America Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 43
Figure 16. North America Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 45
Figure 17. North America Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 46
Figure 18. North America Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 47
Figure 19. North America Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 48
Figure 20. Breakdown of North America Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 50
Figure 21. North America Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 50
Figure 22. North America Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 51
Figure 23. North America Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 52
Figure 24. North America Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 54
Figure 25. North America Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 55
Figure 26. North America Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 56
Figure 27. North America Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 57
Figure 28. North America Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 58
Figure 29. Breakdown of North America Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 60
Figure 30. North America Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 60
Figure 31. North America Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 61
Figure 32. North America Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 62
Figure 33. Breakdown of North America Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 64
Figure 34. North America Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 64
Figure 35. North America Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 65
Figure 36. North America Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 66
Figure 37. North America Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 67
Figure 38. North America Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 68
Figure 39. North America Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 69
Figure 40. North America Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 70
Figure 41. North America Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 71
Figure 42. North America Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 72
Figure 43. Breakdown of North America Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 74
Figure 44. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 75
Figure 45. U.S. Small Molecule CDMO Market, 2021-2031, $ mn 77
Figure 46. Canada Small Molecule CDMO Market, 2021-2031, $ mn 79
Figure 47. Small Molecule CDMO Market in Mexico, 2021-2031, $ mn 81
Figure 48. Growth Stage of North America Small Molecule CDMO Industry over the Forecast Period 83
North America small molecule contract development and manufacturing organization (CDMO) market is projected to grow by 5.3% annually in the forecast period and reach $ 42,793.3 million by 2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures. Highlighted with 24 tables and 48 figures, this 103-page report “North America Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country. Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Active Pharmaceutical Ingredients (API) o Branded Drugs o Generic Drugs • Finished Dosage Formulations (FDF) o Oral Solid Drugs o Injectable Drugs o Semi-solid or Liquid Drugs o Other FDFs Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Preclinical Use • Clinical Use o Phase I o Phase II o Phase III o Phase IV • Commercial Use By Customer Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Pharmaceutical Firms • Biotechnology Firms By Therapeutic Area, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Respiratory Disorders • Metabolic Diseases • Other Therapeutic Areas Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Boehringer Ingelheim Cambrex Corporation Catalent Cipla Covance Inc. Lonza Group Ltd. Medley Pharmaceuticals NatcoPharma Patheon (Thermo Fisher Scientific, Inc.) Piramal Pharma Solutions RedHillBiopharma Siegfried Holding AG STA Pharmaceutical Sun Pharmaceutical Teva (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More